FrancophonIA/ELRC3.0 huggingface dataset:
English: The additional studies showed that including vitamin D3 in the same tablet with alendronic acid could increase vitamin D levels.
Croatian: Dodatnim ispitivanjima utvrđeno je da uključivanje vitamina D3 u istu tabletu s alendronatnom kiselinom može povećati razine vitamina D.
English: Blocking the action of these cells leads to less bone loss.
Croatian: Inhibiranje djelovanja ovih stanica rezultira smanjenjem gubitka kosti.
English: Fosavance must not be used in patients who have abnormalities of the oesophagus, who have hypocalcaemia (low blood calcium levels), or who cannot stand or sit upright for at least 30 minutes.
Croatian: Fosavance se ne smije koristiti u bolesnica koje imaju abnormalnosti jednjaka, koje imaju hipokalkemiju (niske razine kalcija) ili koje ne mogu sjediti uspravno najmanje 30 minuta.
English: The main measure of effectiveness was the reduction in the number of patients with low vitamin D levels after 15 weeks.
Croatian: Glavna mjera djelotvornosti bilo je smanjenje broja bolesnica s niskim razinama vitamina
English: The CHMP decided that Fosavance's benefits are greater than its risks and recommended that it be given marketing authorisation.
Croatian: CHMP je odlučio da koristi od lijeka Fosavance nadmašuju s njim povezane rizike te je preporučio izdavanje odobrenja za stavljanje lijeka u promet.
English: Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Fosavance, including the appropriate precautions to be followed by healthcare professionals and patients.
Croatian: Na temelju tog plana, u sažetku opisa svojstava lijeka kao i u uputi za lijek Fosavance nalaze se sigurnosne informacije, uključujući odgovarajuće mjere opreza kojih se zdravstveni djelatnici i bolesnici trebaju pridržavati.
English: To support the combination of alendronic acid and vitamin D3 in the same tablet, the company also carried out a study in 717 patients with osteoporosis, including 682 women who had been through the menopause, to show Fosavance's ability to increase vitamin D levels.
Croatian: Kako bi se podržala primjena alendronatne kiseline i vitamina D3 u istoj tableti, tvrtka je također provela ispitivanje među 717 bolesnica s osteoporozom, uključujući 682 žene u postmenopauzi, kako bi dokazala sposobnost lijeka Fosavance da poveća razinu vitamina D.
English: Fosavance alendronic acid and colecalciferol
Croatian: Fosavance alendronatna kiselina i kolekalciferol
English: Fosavance (containing either 2,800 or 5,600 IU colecalciferol) is used to treat osteoporosis (a disease that makes bones fragile) in women who have been through the menopause and are at risk of low vitamin D levels.
Croatian: Fosavance (koji sadrži 2 800 ili 5 600 IU kolekaciferola) koristi se za liječenje osteoporoze (bolesti koja čini kosti lomljivima) u žena u postmenopauzi koje su izložene riziku niskih razina vitamina D.
English: It is available as tablets (70 mg alendronic acid and 2,800 international units [IU] colecalciferol; 70 mg alendronic acid and 5,600 IU colecalciferol).
Croatian: Dostupan je kao tablete (70 mg alendronatne kiseline i 2 800 međunarodnih jedinica [IU] kolekalciferola; 70 mg alendronatne kiseline i 5 600 IU kolekalciferola).
English: What is the risk associated with Fosavance?
Croatian: Koji su rizici povezani s lijekom Fosavance?
English: Fosavance 70 mg/5,600 IU is for use in patients who are not taking vitamin D supplements.
Croatian: Fosavance 70 mg/5 600 IU koristi se u bolesnica koje ne uzimaju dodatke vitamina D.
English: Why has Fosavance been approved?
Croatian: Zašto je Fosavance odobren?
English: What is Fosavance?
Croatian: Što je Fosavance?
English: The full EPAR for Fosavance can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Croatian: Cjeloviti EPAR za lijek Fosavance nalazi se na internetskim stranicama Agencije: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports Više informacija o terapiji lijekom Fosavance pročitajte u uputi o lijeku (također dio EPAR-a) ili se obratite svom liječniku ili ljekarniku.
English: This study was extended in 652 patients for a further 24 weeks to compare the effects of continuing with Fosavance 70 mg/2,800 IU on its own or adding another 2,800 IU vitamin D3 (equivalent to using Fosavance 70 mg/5,600 IU).
Croatian: Ovo je ispitivanje prošireno kod 652 bolesnica tijekom daljnja 24 tjedna kako bi se usporedilo djelovanje monoterapije lijekom Fosavance 70 mg/2 800 IU ili dodavanje dodatnih 2 800 IU vitamina D3 (ekvivalent primjeni 70 mg/5 600 IU).
English: What benefit has Fosavance shown during the studies?
Croatian: Koje su koristi lijeka Fosavance dokazane u ispitivanjima?
English: Fosavance is a medicine that contains two active substances: alendronic acid and colecalciferol (vitamin D3).
Croatian: Fosavance je lijek koji sadrži dvije djelatne tvari: alendronatnu kiselinu i kolekalciferol (vitamin D3).
English: In the extension study, similar numbers of patients taking Fosavance 70 mg/2,800 IU and Fosavance 70 mg/5,600 IU had low vitamin D levels (below 6%), but the patients taking Fosavance 70 mg/5,600 IU had greater increases in vitamin D levels over the 24 weeks of the study.
Croatian: U produljenom ispitivanju, podjednak broj bolesnica koje su uzimale lijek Fosavance 70mg/2 800 IU i Fosavance 70 mg/5 600 IU imao je niske koncentracije vitamina D (manje od 6 %), no bolesnice koje su uzimale Fosavance 70 mg/5 600 IU imale su veća povećanja koncentracije vitamina
English: Patients received either Fosavance 70 mg/2,800 IU or alendronic acid only once a week.
Croatian: Bolesnice su primale lijek Fosavance 70 mg/2 800 IU ili alendronatnu kiselinu jednom na tjedan.
English: Patients should also take calcium supplements if they are not getting enough calcium from their diet. For more information, see the package leaflet.
Croatian: Bolesnice također trebaju uzimati dodatke kalcija ako nemaju dovoljne količine kalcija u svojoj prehrani.
English: Fosavance contains two active substances: alendronic acid and colecalciferol (vitamin D3).
Croatian: Fosavance sadrži dvije djelatne tvari: alendronatnu kiselinu i kolekalciferol (vitamin D3).
English: The most common side effects with Fosavance (seen between 1 and 10 patients in 100) are headache, abdominal pain (stomach ache), dyspepsia (heartburn), constipation, diarrhoea, flatulence (gas),
Croatian: Najčešće nuspojave lijeka Fosavance (mogu se javiti kod 1 do 10 osoba na 100) su glavobolja, abdominalna bol (bol u želucu), dispepsija (žgaravica), zatvor, proljev, nadutost (plinovi), čirevi u jednjaku, disfagija (poteškoće u gutanju), abdominalna distenzija (nadutost trbuha), regurgitacija kiseline i mišićnokoštana bol (bol u mišićima, kostima i zglobovima).
English: for the full list of restrictions, see the package leaflet.
Croatian: Potpuni popis ograničenja potražite u uputi o lijeku
English: What is Fosavance used for?
Croatian: Za što se Fosavance koristi?
English: For the full list of all side effects reported with Fosavance, see the package leaflet.
Croatian: Potpuni popis nuspojava zabilježenih pri primjeni lijeka Fosavance potražite u uputi o lijeku.
English: How is Fosavance used?
Croatian: Kako se Fosavance koristi?
English: How does Fosavance work?
Croatian: Kako djeluje Fosavance?
English: After 15 weeks, fewer patients had low vitamin D levels when they took Fosavance 70 mg/2,800 IU (11%) than when they took alendronic acid only (32%).
Croatian: D nakon što su uzimale Fosavance od 70 mg/2 800 IU (11 %) u odnosu na one koji su primale monoterapiju alendronatnom kiselinom (32 %).
English: How has Fosavance been studied?
Croatian: Kako je Fosavance ispitivan?
English: Doses can be increased up to twice more until the most effective dose is reached.
Croatian: Doze se mogu povećavati do dvostruko veće doze sve dok se ne dosegne najdjelotvornija doza.
English: is available as capsules (25, 50, 75, 100, 150, 200, 225 and 300 mg) and can only be obtained with a prescription.
Croatian: Lijek Pregabalin Zentiva k.s. dostupan je u tabletama (25, 50, 75, 100, 150, 200, 225 i 300 mg), a izdaje se samo na recept.
English: This reduces the activity of nerve cells in the brain and spinal cord that are involved in pain, epilepsy and anxiety.
Croatian: To smanjuje aktivnost živčanih stanica u mozgu i leđnoj moždini povezanih s boli, epilepsijom i tjeskobom.
English: Doctors may choose lower doses in patients with kidney problems.
Croatian: Liječnici mogu odrediti manju dozu u bolesnika s bubrežnim problemima.
English: can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Croatian: Cjeloviti EPAR za lijek Pregabalin Zentiva k.s. nalazi se na internetskim stranicama Agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: The active substance in Pregabalin Zentiva k.s., pregabalin, is similar in structure to the body's own ‘neurotransmitter' gamma‑amino butyric acid (GABA), but has very different biological effects.
Croatian: Djelatna tvar lijeka Pregabalin Zentiva k.s., pregabalin, po strukturi je sličan gama-aminobutiričnoj kiselini (GABA), neurotransmiteru u tijelu, no ima vrlo različito biološko djelovanje.
English: Therefore, the CHMP's view was that, as for Lyrica, the benefit outweighs the identified risk.
Croatian: Stoga je stav CHMP-a da, kao i u slučaju lijeka Lyrica, koristi nadmašuju utvrđene rizike.
English: For more information on generic medicines, see the question-and-answer document here.
Croatian: Više informacija o generičkim lijekovima potražite ovdje u dokumentu s pitanjima i odgovorima.
English: contains the same active substance and works in the same way as a ‘reference medicine' already authorised in the European Union (EU) called Lyrica.
Croatian: To znači da Pregabalin Zentiva k.s. sadržava istu djelatnu tvar i djeluje na isti način kao i „referentni lijek” koji je već odobren u Europskoj uniji (EU) pod nazivom Lyrica.
English: is a medicine used to treat adults with the following conditions:
Croatian: Pregabalin Zentiva k.s. je lijek koji se koristi za liječenje odraslih osoba sa sljedećim stanjima:
English: Studies on the benefits and risks of the active substance in the approved uses have already been carried out with the reference medicine, Lyrica, and do not need to be repeated for Pregabalin Zentiva k.s.
Croatian: Ispitivanja o koristima i djelatnoj tvari referentnog lijeka Lyrica u odobrenim uporabama već je provedeno te se ne treba ponavljati za lijek Pregabalin Zentiva k.s.
English: • neuropathic pain (pain due to nerve damage), including peripheral neuropathic pain, such as the pain experienced by patients with herpes zoster (shingles) or nerve disorders caused by diabetes,
Croatian: • neuropatskom boli (boli uslijed oštećenja živca), uključujući perifernu neuropatsku bol, poput boli koju iskuse bolesnici s herpes zosterom (pasac) ili živčanim poremećajem uzrokovanim dijabetesom, i središnjom neuropatskom boli, poput boli koju osjete bolesnici koji imaju ozljedu kralježnične moždine;
English: As for every medicine, the company provided studies on the quality of Pregabalin Zentiva k.s.
Croatian: Kao i za svaki lijek, tvrtka je dostavila ispitivanja o kvaliteti lijeka Pregabalin Zentiva k.s.
English: the dose should be reduced gradually, over at least a week.
Croatian: Prekid terapije lijekom Pregabalin Zentiva k.s. treba također provoditi postupno, tijekom najmanje jednog tjedna.
English: is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.
Croatian: Budući da je lijek Pregabalin Zentiva k.s. generički lijek te je bioekvivalentan referentnom lijeku, smatra se da su njegove koristi i rizici isti kao i kod referentnog lijeka.
English: For more information about treatment with Pregabalin Zentiva k.s., read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Croatian: Više informacija o liječenju lijekom Pregabalin Zentiva k.s. pročitajte u uputi o lijeku (također dio EPAR-a), odnosno obratite se svom liječniku ili ljekarniku.
English: This is a summary of the European public assessment report (EPAR) for Pregabalin Zentiva k.s.
Croatian: Ovo je sažetak europskoga javnog izvješća o procjeni (EPAR) lijeka Pregabalin Zentiva k.s.
English: For practical information about using Pregabalin Zentiva k.s., patients should read the package leaflet or contact their doctor or pharmacist.
Croatian: Praktične informacije o primjeni lijeka Pregabalin Zentiva k.s. bolesnici trebaju pročitati u uputi o lijeku, odnosno obratiti se svom liječniku ili ljekarniku.
English: What measures are being taken to ensure the safe and effective use of Pregabalin Zentiva k.s.
Croatian: Koje se mjere poduzimaju kako bi se osigurala sigurna i učinkovita primjena lijeka Pregabalin Zentiva k.s.?
English: (epileptic fits starting in one specific part of the brain) that cannot be controlled with their current treatment;
Croatian: • epilepsijom, kada se koristi kao dodatna terapija postojećoj terapiji u bolesnika koji imaju parcijalne napadaje (epileptične napadaje koji izbijaju u jednom specifičnom djelu mozga) koje nije moguće kontrolirati aktualnom terapijom;
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) concluded that, in accordance with EU requirements, Pregabalin Zentiva k.s.
Croatian: Odbor za lijekove za humanu uporabu (CHMP) pri Agenciji zaključio je kako je, u skladu sa zahtjevima EU-a, potvrđeno da Pregabalin Zentiva k.s. posjeduje usporedivu kakvoću te je bioekvivalentan s lijekom Lyrica.
English: It is not intended to provide practical advice on how to use Pregabalin Zentiva k.s.
Croatian: Svrha sažetka nije davati praktične savjete o primjeni lijeka Pregabalin Zentiva k.s.
English: What are the benefits and risks of Pregabalin Zentiva k.s.
Croatian: Koje su koristi i rizici lijeka Pregabalin Zentiva k.s.?
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Pregabalin Zentiva k.s.
Croatian: Preporuke i mjere opreza kojih se zdravstveni radnici i bolesnici trebaju pridržavati u cilju sigurne i učinkovite primjene lijeka Pregabalin Zentiva k.s. nalaze se u sažetku opisa svojstava lijeka i u uputi o lijeku.
English: Other information about Pregabalin Zentiva k.s.
Croatian: Ostale informacije o lijeku Pregabalin Zentiva k.s.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Pregabalin Zentiva k.s.
Croatian: Odbor je preporučio odobrenje lijeka Pregabalin Zentiva k.s. za korištenje u EU-u.
English: Why is Pregabalin Zentiva k.s.
Croatian: Zašto je Pregabalin Zentiva k.s. odobren?
English: contains the active substance pregabalin.
Croatian: Pregabalin Zentiva k.s. sadrži djelatnu tvar pregabalin.
English: and what is it used for?
Croatian: Što je Pregabalin Zentiva k.s. i za što se koristi?
English: How has Pregabalin Zentiva k.s.
Croatian: Kako djeluje Pregabalin Zentiva k.s.?
English: In the future, if the fish are exposed to the virus, the immune system will be able to respond more quickly.
Croatian: Ako ribe u budućnosti budu izložene virusu, imunosni sustav moći će brže reagirati.
English: This summary was last updated in April 2016.
Croatian: Sažetak je posljednji put ažuriran u 04.2016.
English: The full EPAR for Clynav can be found on the Agency's website: ema.europa.eu/Find medicine/Veterinary medicines/European public assessment reports.
Croatian: Cjeloviti EPAR za VMP Clynav nalazi se na internetskim stranicama Agencije: ema.europa.eu/Find medicine/Veterinary medicines/European public assessment reports.
English: Protection lasts approximately three months after vaccination at average water temperature of 12 ±2 °C.
Croatian: Imunitet traje otprilike tri mjeseca nakon cijepljenja pri prosječnoj temperaturi vode od 12 ±2 °C.
English: Why is Clynav approved?
Croatian: Zašto je Clynav odobren?
English: The immune system recognises these virus proteins as ‘foreign' and makes defences against them.
Croatian: Imunosni sustav prepoznaje te virusne proteine kao „strana tijela” i stvara obrambeni mehanizam protiv njih.
English: The most common side effects with Clynav (which may affect more than 1 in 10 fish) are short lived changes in swimming behaviour for up to two days, altered pigmentation (colouration) for up to seven days and lack of appetite for up to nine days.
Croatian: Najčešće nuspojave VMP-a Clynav (mogu se javiti u više od 1 na 10 riba) su prolazne promjene u ponašanju kod plivanja u trajanju do dva dana, promjene pigmentacije (boje) u trajanju do sedam dana i gubitak apetita u trajanju do devet dana.
English: The vaccine is given to anaesthetised fish as a single injection into epaxial muscle (muscle of the upper half of the fish) in the area to the front and side of the dorsal fin.
Croatian: Cjepivo se daje ribama pod anestezijom kao jedna injekcija u epaksijalni mišić (mišić u gornjem dijelu tijela ribe) u području ispred i bočno od dorzalne peraje.
English: Vaccines work by ‘teaching' the immune system (the body's natural defences)
Croatian: Cjepiva djeluju „učeći” imunosni sustav (prirodnu obranu tijela) kako se zaštititi od bolesti.
English: Needle injuries at the site of injection are common following vaccination and can persist for at least 90 days.
Croatian: Ozljede od uboda igle na mjestu injekcije vrlo su česte nakon primjene cjepiva i mogu potrajati najmanje 90 dana.
English: What is Clynav and what is it used for?
Croatian: Što je Clynav i za što se koristi?
English: The withdrawal period for fish from Atlantic salmon treated with Clynav is ‘zero' days, which means there is no mandatory waiting time.
Croatian: Karencija za atlantskog lososa liječenog VMP-om Clynav iznosi „nula” dana, tj. nema obveznog razdoblja čekanja.
English: Direct contact should be avoided and protective equipment (for example protective gloves) should be worn when handling the medicine.
Croatian: Pri rukovanju veterinarsko-medicinskim proizvodom treba izbjegavati izravni kontakt i nositi zaštitnu opremu (na primjer zaštitne rukavice).
English: The time for protection to develop following vaccination depends on the water temperature: protection starts within 399 degree days, calculated as mean water temperature in °C multiplied by number of days, for example 40 days at a water temperature of 10 °C.
Croatian: Početak imuniteta nakon primjene cjepiva ovisi o temperaturi vode: imunitet nastupa unutar 399 stupnja dana, izračunato kao umnožak srednje temperature vode u °C i broja dana, na primjer 40 dana pri temperaturi vode od 10 °C.
English: Pancreas disease in Atlantic salmon can lead to impaired daily weight gain, lesions of the heart, pancreas and skeletal muscle as well as death.
Croatian: Bolest gušterače atlantskog lososa može uzrokovati smanjen dnevni prirast tjelesne težine, oštećenja srca, gušterače i skeletnih mišića te smrt.
English: Six laboratory studies were conducted in fresh water and sea water to show how effective the vaccine was in protecting salmon from disease caused by SPDV.
Croatian: Provedeno je šest laboratorijskih ispitivanja u slatkoj i morskoj vodi kako bi se dokazala učinkovitost cjepiva u zaštiti lososa od bolesti uzrokovane SPDV-om.
English: In case of accidental needle stick or self-injection, medical advice should be sought immediately and the package leaflet or label shown to the doctor.
Croatian: U slučaju nehotičnog uboda iglom ili samoinjektiranja treba odmah potražiti liječnički savjet te pokazati uputu o VMP-u ili etiketu.
English: What are the risks associated with Clynav?
Croatian: Koji su rizici povezani s VMP-om Clynav?
English: It is not intended to provide practical advice on how to use Clynav.
Croatian: Svrha sažetka nije davati praktične savjete o primjeni VMP-a Clynav.
English: This is a summary of the European public assessment report (EPAR) for Clynav.
Croatian: Ovo je sažetak europskoga javnog izvješća o procjeni (EPAR) veterinarsko-medicinskog proizvoda Clynav.
English: The Agency's Committee for Medicinal Products for Veterinary Use (CVMP) concluded that Clynav's benefits are greater than its risks and recommended that it be approved for use in the EU.
Croatian: Odbor za veterinarsko-medicinske proizvode (CVMP) pri Agenciji odlučio je da koristi od VMP-a Clynav nadmašuju s njim povezane rizike te je preporučio njegovo odobrenje za primjenu u Europskoj uniji.
English: Clynav is a veterinary vaccine used in Atlantic salmon to protect them against pancreas disease caused by salmonid alphavirus subtype 3 (SAV3).
Croatian: Clynav je veterinarsko cjepivo koje se primjenjuje u atlantskog lososa radi zaštite od bolesti gušterače koju uzrokuje salmonidni alfavirus podtip 3 (SAV3).
English: Following artificial infection by co-habitation with infected salmon 29 days and 3 months after vaccination, fish vaccinated with Clynav had improved weight gain, reduced heart, pancreas and skeletal muscle lesions and reduced risk of death compared to fish injected with the dummy saline injection.
Croatian: Tri mjeseca nakon cijepljenja, nakon infekcije umjetno izazvane kohabitacijom sa zaraženim lososima 29 dana, ribe cijepljene VMP-om Clynav imale su bolji dnevni prirast, manja oštećenja srca, gušterače i skeletnih mišića te je rizik od njihove smrti bio manji, u usporedbi s ribama kojima je ubrizgana fiziološka otopina bez djelatne tvari.
English: Clynav is a DNA vaccine.
Croatian: VMP Clynav je DNK cjepivo.
English: Other information about Clynav:
Croatian: Ostale informacije o VMP-u Clynav
English: Clynav is available as a solution for injection and can only be obtained with a prescription.
Croatian: VMP Clynav dostupan je kao otopina za injekciju i izdaje se samo na veterinarski recept.
English: Clynav contains as active substance a DNA plasmid (a small piece of DNA) containing the genetic code for making salmon pancreas disease virus proteins.
Croatian: VMP Clynav sadržava djelatnu tvar DNK plazmid (mali dio DNK-a) koji sadržava genetsku šifru za stvaranje virusnih proteina bolesti gušterače lososa.
English: A main laboratory model study looked at the signs of pancreas disease in fish given Clynav compared with a dummy saline injection.
Croatian: U glavnom laboratorijskom modelu ispitivanja istraživala se pojava znakova bolesti gušterače u riba koje su primile VMP Clynav u usporedbi s ubrizganom fiziološkom otopinom bez djelatne tvari.
English: The withdrawal period is the time required after administration of a medicine before an animal can be slaughtered and the meat used for human consumption.
Croatian: Karencija je vrijeme koje treba proći nakon primjene VMP-a do klanja životinje i korištenja mesa za prehranu ljudi.
English: What benefits of Clynav have been shown in studies?
Croatian: Koje su koristi VMP-a Clynav dokazane u ispitivanjima?
English: How does Clynav work?
Croatian: Kako djeluje Clynav?
English: Clynav contains a DNA plasmid which, once injected into fish, will lead to the production of salmon pancreas disease virus (SPDV) proteins.
Croatian: VMP Clynav sadržava DNK plazmid, koji nakon injektiranja u ribu dovodi do stvaranja virusnih proteina bolesti gušterače lososa (SPDV).
English: Clynav salmon pancreas disease vaccine (recombinant DNA plasmid)
Croatian: Clynav cjepivo za bolest gušterače lososa (rekombinantni DNK plazmid)
English: For practical information about using Clynav, animal owners or keepers should read the package leaflet or contact their veterinarian or pharmacist.
Croatian: Praktične informacije o primjeni VMP-a Clynav vlasnici životinja ili uzgajivači trebaju pročitati u uputi o VMP-u, odnosno trebaju se obratiti svojem veterinaru ili ljekarniku.
English: For more information about treatment with Clynav, animal owners or keepers should read the package leaflet or contact their veterinarian or pharmacist.
Croatian: Dodatne informacije o terapiji VMP-om Clynav vlasnici životinja ili uzgajivači trebaju pročitati u uputi o VMP-u, odnosno trebaju se obratiti svojem veterinaru ili ljekarniku.
English: How is Clynav used?
Croatian: Kako se Clynav koristi?